Published in Proc Natl Acad Sci U S A on October 25, 2004
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol (2008) 11.02
Inflammatory bowel disease. Annu Rev Immunol (2010) 7.10
Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A (2005) 3.32
Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol (2008) 2.68
Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol (2007) 2.67
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A (2006) 2.31
A key role of dendritic cells in probiotic functionality. PLoS One (2007) 1.73
Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol (2007) 1.56
Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol (2007) 1.45
Lipoxins: resolutionary road. Br J Pharmacol (2009) 1.35
Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J (2007) 1.20
Annexin A1 regulates intestinal mucosal injury, inflammation, and repair. J Immunol (2008) 1.18
High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation. Lipids Health Dis (2013) 1.08
Bacteria in the intestine, helpful residents or enemies from within? Infect Immun (2008) 1.07
A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proc Natl Acad Sci U S A (2010) 1.01
Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. Prostaglandins Leukot Essent Fatty Acids (2008) 0.99
Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets. Antioxid Redox Signal (2013) 0.99
Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One (2012) 0.98
Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice. World J Gastroenterol (2010) 0.98
Anti-inflammatory and pro-resolving properties of benzo-lipoxin A(4) analogs. Prostaglandins Leukot Essent Fatty Acids (2009) 0.93
Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. Br J Pharmacol (2007) 0.93
Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front Immunol (2012) 0.92
Oxidative stress induced mechanisms in the progression of periodontal diseases and cancer: a common approach to redox homeostasis? Cancers (Basel) (2010) 0.87
Lack of effects of acemetacin on signalling pathways for leukocyte adherence may explain its gastrointestinal safety. Br J Pharmacol (2008) 0.86
Acetylsalicylic Acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators. Biomed Res Int (2013) 0.84
CEACAM1 and the regulation of mucosal inflammation. Mucosal Immunol (2008) 0.84
Resolution of Inflammation: What Controls Its Onset? Front Immunol (2016) 0.84
Resolution of inflammation in periodontitis. J Periodontol (2005) 0.83
Can vagus nerve stimulation halt or ameliorate rheumatoid arthritis and lupus? Lipids Health Dis (2011) 0.81
BML-11, a lipoxin receptor agonist, protected carbon tetrachloride-induced hepatic fibrosis in rats. Inflammation (2013) 0.80
Lipoxin A4 inhibits immune cell binding to salivary epithelium and vascular endothelium. Am J Physiol Cell Physiol (2011) 0.79
Commonality of defensive roles of COX-2 in the lung and gut. Am J Pathol (2006) 0.77
Neutrophils as protagonists and targets in chronic inflammation. Nat Rev Immunol (2017) 0.75
Regulated spatial distribution of cyclooxygenases and lipoxygenases in Crohn's ulcer. Mediators Inflamm (2006) 0.75
In Vivo Availability of Pro-Resolving Lipid Mediators in Oxazolone Induced Dermal Inflammation in the Mouse. PLoS One (2015) 0.75
Expression of concern. Proc Natl Acad Sci U S A (2008) 0.75
Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease. Mediators Inflamm (2016) 0.75
Renin-angiotensin-aldosterone system in insulin resistance and metabolic syndrome. J Transl Int Med (2016) 0.75
The Dual Role of Neutrophils in Inflammatory Bowel Diseases. J Clin Med (2016) 0.75
Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology (1998) 9.58
Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med (1995) 6.89
Experimental models of inflammatory bowel disease. Gastroenterology (1995) 6.28
Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology (1994) 4.57
Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A (1995) 3.72
Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med (1998) 3.50
Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology (1989) 3.24
Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med (2000) 2.93
Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry (1995) 2.75
Improved procedure for the isolation of functionally active lymphoid cells from the murine intestine. J Immunol Methods (1987) 2.50
Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol (1997) 2.35
Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med (1996) 2.30
Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci U S A (1999) 2.21
Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology (1999) 2.15
Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol (2002) 1.95
Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J Exp Med (2002) 1.87
Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol (2002) 1.57
Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat (2002) 1.56
Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med (1999) 1.55
Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol (2003) 1.52
Galectin-1 suppresses experimental colitis in mice. Gastroenterology (2003) 1.41
NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci U S A (2002) 1.36
Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation. J Biol Chem (2000) 1.35
Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity (2002) 1.25
Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology (1999) 1.22
Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. EMBO J (2003) 1.22
Temporal distribution of neuronal and inducible nitric oxide synthase and nitrotyrosine during colitis in rats. Neurogastroenterol Motil (1999) 1.06
Lipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases. Am J Pathol (2002) 1.05
A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J Immunol (2003) 1.03
An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J Immunol (2002) 1.01
Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. J Med Chem (2004) 0.98
A magic bullet for mucosal protection...and aspirin is the trigger! Trends Pharmacol Sci (2003) 0.97
Neutrophil-independence of the initiation of colonic injury. Comparison of results from three models of experimental colitis in the rat. Dig Dis Sci (1994) 0.94
Effects of local budesonide treatment on the cell-mediated immune response in acute and relapsing colitis in rats. Dig Dis Sci (1998) 0.93
Differential role of selectins in experimental colitis. Gastroenterology (2001) 0.92
TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab (2009) 6.91
Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 5.12
Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood (2002) 3.58
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J (2006) 3.37
Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology (2003) 3.21
Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology (2006) 2.98
Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci (2004) 2.64
Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology (2005) 2.58
TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab (2011) 2.17
Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol (2002) 2.16
Concern NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. Circulation (2002) 2.09
The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology (2006) 2.08
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology (2004) 1.96
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res (2009) 1.96
Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol (2002) 1.95
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem (2002) 1.85
Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A (2004) 1.76
The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol (2009) 1.69
Synthesis and biological effects of hydrogen sulfide (H2S): development of H2S-releasing drugs as pharmaceuticals. J Med Chem (2010) 1.63
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther (2005) 1.56
Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. J Am Coll Cardiol (2004) 1.52
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 1.47
A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc Natl Acad Sci U S A (2005) 1.45
Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci (2009) 1.45
PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology (2004) 1.42
Galectin-1 suppresses experimental colitis in mice. Gastroenterology (2003) 1.41
Pseudo-pseudo-obstruction. Eur J Gastroenterol Hepatol (2004) 1.40
Idebenone treatment in Leber's hereditary optic neuropathy. Brain (2011) 1.39
The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology (2005) 1.38
The inducible nitric oxide synthase inhibitor BBS-2 prevents acute lung injury in sheep after burn and smoke inhalation injury. Am J Respir Crit Care Med (2003) 1.38
NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci U S A (2002) 1.36
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology (2002) 1.33
Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability. Proc Natl Acad Sci U S A (2003) 1.32
A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther (2005) 1.30
Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol (2008) 1.26
Visual system involvement in patients with Friedreich's ataxia. Brain (2008) 1.25
Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity (2002) 1.25
Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation (2005) 1.24
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res (2009) 1.23
Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med (2007) 1.23
The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol (2006) 1.20
CD1-restricted recognition of exogenous and self-lipid antigens by duodenal gammadelta+ T lymphocytes. J Immunol (2007) 1.20
Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J (2007) 1.20
Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism. Can J Physiol Pharmacol (2003) 1.17
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther (2005) 1.16
Long-term study on the effects of visual biofeedback and muscle training as a therapeutic modality in pelvic floor dyssynergia and slow-transit constipation. Dis Colon Rectum (2004) 1.15
Retracted A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2004) 1.15
Pasta naturally enriched with isoflavone aglycons from soy germ reduces serum lipids and improves markers of cardiovascular risk. J Nutr (2007) 1.15
Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J Biol Chem (2001) 1.14
Magnetic resonance diagnostic markers in clinically sporadic prion disease: a combined brain magnetic resonance imaging and spectroscopy study. Brain (2009) 1.13
Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci U S A (2002) 1.13
Anisakis pegreffi etiological agent of gastric infections in two Italian women. Foodborne Pathog Dis (2009) 1.13
The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta (2010) 1.11
Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A (2003) 1.11
The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One (2011) 1.11
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation (2013) 1.11
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther (2005) 1.11
Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord (2005) 1.11
Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol (2004) 1.10
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity. J Med Chem (2011) 1.09
Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J (2003) 1.09